专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

WO2005118642A3 BISPECIFIC FUSION ANTIBODIES WITH ENHANCED SERUM HALF-LIFE 审中-公开
标题翻译：具有增强血清半衰期的双相融合抗体
公开(公告)号：WO2005118642A3
公开(公告)日：2006-03-23
申请号：PCT/GB2005002163
申请日：2005-05-31
申请人： DOMANTIS LTD , HOLT LUCY J , TOMLINSON IAN M
发明人： HOLT LUCY J , TOMLINSON IAN M
IPC分类号： C07K16/46 , A61K47/48 , C07K16/00 , C07K16/18 , C07K16/44
CPC分类号： C07K14/545 , A61K47/6811 , A61K47/6843 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/94 , C07K2319/00 , C07K2319/31
摘要： Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.
摘要翻译：提供药物组合物，融合物和缀合物。药物融合物和缀合物含有与结合血清白蛋白的抗体的抗原结合片段融合或缀合的治疗剂或诊断剂。与非共轭或未融合的治疗或诊断剂相比，药物组合物，融合物和缀合物具有更长的体内半衰期。

52. 发明申请

WO2005033130A2 SYNTHETIC LG BINDING DOMAINS OF PROTEIN L 审中-公开
标题翻译：合成LG蛋白质结合域L
公开(公告)号：WO2005033130A2
公开(公告)日：2005-04-14
申请号：PCT/GB2004004174
申请日：2004-10-01
申请人： DOMANTIS LTD , ENEVER CAROLYN , TOMLINSON IAN
发明人： ENEVER CAROLYN , TOMLINSON IAN
IPC分类号： C07K14/195 , C07K14/315 , C07K14/00
CPC分类号： C07K14/315
摘要： Isolated synthetic Ig binding domain of Protein L having enhanced binding affinity for an antibody VK domain, said binding affinity being enhanced over that of the wild type 131 binding domain of Protein L, said isolated Ig binding domain exhibiting at least one mutation of at least one amino acid residue corresponding to residues 25, 28, 31, 33-41, 45, 49, 50, 52-59, 61, 62, 76 and 78 of seq id no 1.
摘要翻译：分离的蛋白L的合成Ig结合结构域对抗体VK结构域具有增强的结合亲和力，所述结合亲和力比蛋白L的野生型131结合结构域的结合亲和力提高，所述分离的Ig结合结构域显示至少一个至少一个对应于序列号1的残基25,28,31,33-41,45,49,50,52-59,61,62,76和78的氨基酸残基。

53. 发明申请

WO2004058822A3 GENERATION OF IMMUNOGLOBULIN MOLECULES WITH PREDETERMINED SPECIFICITY 审中-公开
标题翻译：具有预测特异性的免疫球蛋白分子的产生
公开(公告)号：WO2004058822A3
公开(公告)日：2005-03-17
申请号：PCT/GB0305657
申请日：2003-12-24
申请人： DOMANTIS LTD , WINTER GREG , TOMLINSON IAN , IGNATOVICH OLGA
发明人： WINTER GREG , TOMLINSON IAN , IGNATOVICH OLGA
IPC分类号： C07K16/00 , C12N15/13 , C07K16/46 , C12N15/63
CPC分类号： C07K16/005
摘要： The present invention relates to a method for the generation of immunoglobulin molecules of predetermined specificity. In particular, the invention relates to a method for the retargeting of the epitope binding specificity of one or more antibodies using single variable domains which exhibit a dominant epitope binding specificity.
摘要翻译：本发明涉及产生具有预定特异性的免疫球蛋白分子的方法。特别地，本发明涉及使用显示优势表位结合特异性的单个可变结构域重定向一种或多种抗体的表位结合特异性的方法。

54. 发明申请

WO2004003019A2 LIGAND 审中-公开
标题翻译：配体
公开(公告)号：WO2004003019A2
公开(公告)日：2004-01-08
申请号：PCT/GB0302804
申请日：2003-06-30
申请人： DOMANTIS LTD , WINTER GREG , TOMLINSON IAN , IGNATOVICH OLGA , HOLT LUCY , DE ANGELIS ELENA
发明人： WINTER GREG , TOMLINSON IAN , IGNATOVICH OLGA , HOLT LUCY , DE ANGELIS ELENA
IPC分类号： C07K16/00 , C07K16/18 , C07K16/24 , C07K16/28 , C07K16/40 , C07K16/42 , C07K16/46 , C12N15/13
CPC分类号： C07K16/18 , C07K16/241 , C07K16/2875 , C07K16/2878 , C07K16/40 , C07K16/42 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/53 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/622 , C07K2317/626 , C07K2317/92 , C07K2318/20
摘要： The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.
摘要翻译：本发明提供了包含具有第一结合特异性的第一免疫球蛋白可变结构域和具有第二结合特异性的互补或非互补免疫球蛋白可变结构域的双重特异性配体。

55. 发明申请

WO03002609A3 DUAL-SPECIFIC LIGAND AND ITS USE 审中-公开
标题翻译：双特殊配对及其使用
公开(公告)号：WO03002609A3
公开(公告)日：2003-08-21
申请号：PCT/GB0203014
申请日：2002-06-28
申请人： DOMANTIS LTD , WINTER GREG , IGNATOVICH OLGA , TOMLINSON IAN
发明人： WINTER GREG , IGNATOVICH OLGA , TOMLINSON IAN
IPC分类号： G01N33/533 , C07K16/18 , C07K16/40 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N21/78 , G01N33/535 , C12N15/79 , G01N33/542 , G01N33/577 , G01N33/68
CPC分类号： C07K16/30 , C07K16/18 , C07K16/40 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/569 , C07K2317/62 , C07K2317/622 , C07K2319/00
摘要： The invention provides a dual-specific ligand comprising a first single immunoglobulin variable domain having a first binding specificity and a complementary immunoglobulin single variable domain having a second binding specificity.
摘要翻译：本发明提供了双特异性配体，其包含具有第一结合特异性的第一单个免疫球蛋白可变结构域和具有第二结合特异性的互补免疫球蛋白单可变结构域。

56. 发明申请

US20130109846A1 COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE 有权
公开(公告)号：US20130109846A1
公开(公告)日：2013-05-02
申请号：US13415914
申请日：2012-03-09
申请人： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
发明人： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC分类号： C07K16/28
CPC分类号： C07K16/2818 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K2317/31 , C07K2317/569 , C07K2317/73
摘要： Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.

57. 发明申请

US20100028354A1 COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE 有权
标题翻译： CD28结合的组合物单一使用方法和使用方法
公开(公告)号：US20100028354A1
公开(公告)日：2010-02-04
申请号：US12505166
申请日：2009-07-17
申请人： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
发明人： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC分类号： A61K39/395 , C07K16/00 , A61P37/00
CPC分类号： C07K16/2818 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K2317/31 , C07K2317/569 , C07K2317/73
摘要： Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
摘要翻译：公开了单价结合CD28的结构域抗体。对CD28结合而言是单价的域抗体可抑制CD28活性。在一个方面，结构域抗体由一个方面组成或包含单个免疫球蛋白可变区，其特异性结合并拮抗CD28的活性，一方面，没有实质上激动的CD28活性。另一方面，结构域抗体是人结构域抗体。本公开还包括在个体中拮抗CD80和/或CD86相互作用的方法以及涉及与CD28相互作用的CD80和/或CD86相互作用的疾病或病症的方法，所述方法涉及对个体施用结构域抗体。

58. 发明申请

US20120201814A1 COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE 有权
标题翻译： CD28结合的组合物单一使用方法和使用方法
公开(公告)号：US20120201814A1
公开(公告)日：2012-08-09
申请号：US13416033
申请日：2012-03-09
申请人： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
发明人： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC分类号： A61K39/395 , A61P29/00 , A61P37/02 , A61P37/00 , A61P37/06
CPC分类号： C07K16/2818 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K2317/31 , C07K2317/569 , C07K2317/73
摘要： Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
摘要翻译：公开了单价结合CD28的结构域抗体。对CD28结合而言是单价的域抗体可抑制CD28活性。在一个方面，结构域抗体由一个方面组成或包含单个免疫球蛋白可变区，其特异性结合并拮抗CD28的活性，一方面，没有实质上激动的CD28活性。另一方面，结构域抗体是人结构域抗体。本公开还包括在个体中拮抗CD80和/或CD86相互作用的方法以及涉及与CD28相互作用的CD80和/或CD86相互作用的疾病或病症的方法，所述方法涉及对个体施用结构域抗体。

59. 发明授权

US07829096B2 CD40L-specific monovalent polypeptides 有权
标题翻译： CD40L特异性单价多肽
公开(公告)号：US07829096B2
公开(公告)日：2010-11-09
申请号：US12387421
申请日：2009-05-01
申请人： Steven Grant , Haiqun Liu , Kevin Moulder
发明人： Steven Grant , Haiqun Liu , Kevin Moulder
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2875 , C07K2317/565 , C07K2317/569 , C07K2317/76
摘要： The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
摘要翻译：本发明涉及单价结合CD40L的抗体多肽。 CD40L结合的一价抗体多肽可以抑制CD40L活性，同时避免可能发生在能够进行DC40L二价或多价结合的抗体的潜在的不良作用。一方面，单价抗CD40L抗体多肽由特异性结合并拮抗DC40L活性的单个免疫球蛋白可变区组成或包含，优选不具有实质上激动的CD40活性。另一方面，单价抗CD40L抗体多肽是人抗体多肽。本发明还包括拮抗个体中CD40 / CD40L相互作用的拮抗作用的方法以及治疗涉及CD40 / DC40L相互作用的疾病或病症的方法，涉及向个体施用单价抗CD40L抗体多肽的方法。

60. 发明申请

US20040009507A1 Concatenated nucleic acid sequence 审中-公开
标题翻译：连锁核酸序列
公开(公告)号：US20040009507A1
公开(公告)日：2004-01-15
申请号：US10412382
申请日：2003-04-11
申请人： Domantis, Ltd.
发明人： Gregory Paul Winter , Laurent Jespers , Ignace Lasters , Peter Wang
IPC分类号： C12Q001/68 , C07H021/04 , C12P019/34
CPC分类号： C40B40/02 , C12N15/10 , C12N15/1037 , C12N15/66
摘要： An in vitro method for constructing a concatenated head-to-tail repertoire of target nucleic acid sequences is revealed. In particular, the method relates to cycles of concatenation whereby after a single cycle of concatenation, not more than two identical copies of each target nucleic acid sequence are linked together head-to-tail on the same molecule of DNA. The present method ensures that each molecule of a concatenated repertoire is derived from a single template target sequence of the starting repertoire.
摘要翻译：揭示了用于构建目标核酸序列的连接的头对头序列的体外方法。特别地，该方法涉及级联的循环，其中在单次循环的连接之后，每个靶核酸序列的不超过两个相同的拷贝在DNA的相同分子上以头对尾连接在一起。本发明的方法确保连接的所有组成部分的每个分子来自起始集合体的单个模板目标序列。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式